Elevance Health stock gains on Q2 2026 earnings beat and guidance raise
Published on 09/14/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health stock (ISIN US2855211023) is trading on a solid fundamental base after the health insurer beat expectations in its second-quarter 2026 results and raised full-year guidance, with the latest quotes around USD 418.72 as of September 14, 2026 per recent market data. According to Scanx Trade on September 13, 2026, Elevance Health reported adjusted diluted EPS of USD 7.45 for Q2 2026, well above the analyst consensus estimate of USD 6.21, and operating revenue of USD 49.826 billion for the quarter.
Q2 2026 earnings beat supports Elevance Health stock
The most recent earnings report for the three months ended June 30, 2026 is a key driver for Elevance Health stock, showing that adjusted EPS of USD 7.45 in Q2 2026 exceeded the consensus estimate of USD 6.21 by USD 1.24 per share, signaling a robust earnings surprise for investors. According to Scanx Trade, operating revenue for Elevance Health reached USD 49.826 billion in Q2 2026, surpassing the consensus estimate of USD 48.69 billion and rising slightly from USD 49.4 billion in Q2 2025.
The same overview from Scanx Trade indicates that Elevance Health generated operating gain of USD 1.8 billion in Q2 2026 compared with USD 2.4 billion in Q2 2025, while adjusted operating gain declined from USD 2.5 billion to USD 1.8 billion over the same period, and adjusted operating margin narrowed from 5.0 percent in Q2 2025 to 3.6 percent in Q2 2026. For investors, this means that while top-line growth and EPS have surprised positively, margins and operating profitability have come under pressure compared with the prior year.
Guidance raise and dividend underpin investor confidence
Beyond the quarterly numbers, Elevance Health has also adjusted its outlook for the current year, a move that supports sentiment around Elevance Health stock. According to Scanx Trade, the company raised its full-year 2026 guidance following the Q2 2026 results, reflecting management’s confidence in the earnings trajectory and the resilience of its Health Benefits and CarelonRx businesses.
Income-oriented shareholders are also watching the dividend stream. On July 14, 2026, Elevance Health’s board declared a third-quarter 2026 dividend of USD 1.72 per share, payable on September 25, 2026 to shareholders of record on September 10, 2026, as reported by Scanx Trade. This confirmed dividend for the third quarter provides a tangible cash return component alongside the earnings growth story.
Valuation perspectives add another layer to the picture. A recent piece on GuruFocus dated September 13, 2026 highlights that Elevance Health shares around USD 418.72 were viewed as approximately 13.4 percent undervalued relative to a GF Value estimate of USD 483.36, with the article emphasizing dividend sustainability as a core part of the investment case.
Analyst views and stock level around recent valuation
Analyst reactions to the strong Q2 2026 numbers have been reflected in recent price target moves. According to Scanx Trade, Wells Fargo raised its price target on Elevance Health stock to USD 492 following the Q2 2026 earnings release, while RBC lowered its price target to USD 424, indicating differing views about upside potential and risks.
In trading following the Q2 announcement, Elevance Health shares reacted positively. As noted by Scanx Trade, Elevance Health stock rose about 1.8 percent to USD 397.20 in pre-market trading immediately after the Q2 2026 earnings release, reflecting investor appreciation for the earnings beat and the guidance raise.
More recently, data cited in a commentary on GuruFocus indicates that Elevance Health stock was trading at around USD 418.72 as of mid September 2026, with that level standing below the GF Value estimate of USD 483.36 and suggesting a valuation discount of approximately 13.4 percent under the GF Value framework. For investors, the combination of an earnings beat, a raised guidance, a confirmed dividend and a moderate discount to intrinsic value estimates is an important part of the current investment narrative.
Elevance Health stock price and trading snapshot
Elevance Health stock is listed on the New York Stock Exchange under the ticker ELV, and recent trading around USD 418.72 as of September 14, 2026 positions the shares below some of the cited analyst targets such as the USD 492 level from Wells Fargo and close to the RBC target of USD 424. This price region also sits beneath the GF Value estimate of USD 483.36 mentioned by GuruFocus, underscoring that the market is still debating the appropriate valuation for the health insurer after its Q2 2026 results.
Key data on Elevance Health stock
- Company: Elevance Health Inc.
- ISIN: US2855211023
- Ticker: ELV
- Trading venue: NYSE
- Price (as of September 14, 2026): 418.72 USD
- Market capitalization: [value] USD (as of September 14, 2026)
- Sector / Industry: Health Care / Managed Health Care
- Index membership: S&P 500
